Emerging drugs for secondary hyperparathyroidism.

Area of Science:

• Nephrology
• Endocrinology
• Pharmacology

Background:

• Secondary hyperparathyroidism (SHPT) is a progressive complication of chronic kidney disease (CKD).
• SHPT involves elevated parathyroid hormone (PTH), gland hyperplasia, and mineral metabolism abnormalities.
• These disturbances contribute to CKD-mineral and bone disorder (CKD-MBD), impacting quality of life and survival.

Purpose of the Study:

• To review the pathogenesis of SHPT.
• To discuss current and emerging therapeutic approaches for SHPT.
• To highlight the importance of managing mineral metabolism in CKD patients.

Main Methods:

• Literature review of SHPT pathogenesis and treatment.
• Analysis of current therapeutic strategies including diet, phosphate binders, vitamin D analogs, calcimimetics, and parathyroidectomy.
• Discussion of novel drugs in development for SHPT.

Main Results:

• Mineral abnormalities are common early in CKD and prevalent in dialysis patients.
• Current SHPT therapies aim to maintain PTH, calcium, and phosphorus within target ranges.
• Emerging therapies show potential to overcome limitations of existing treatments.

Conclusions:

• SHPT and associated mineral abnormalities increase mortality risk in CKD patients.
• Newly developed compounds may offer improved SHPT management.
• Effective emerging therapies could normalize mineral metabolism, improve adherence, reduce side effects, and enhance long-term outcomes for dialysis patients, mitigating CKD-MBD risks.